These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27872102)

  • 1. E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma.
    Spector ME; Sacco AG; Bellile E; Taylor JMG; Jones T; Sun K; Brown WC; Birkeland AC; Bradford CR; Wolf GT; Prince ME; Moyer JS; Malloy K; Swiecicki P; Eisbruch A; McHugh JB; Chepeha DB; Rozek L; Worden FP
    Clin Cancer Res; 2017 Jun; 23(11):2723-2729. PubMed ID: 27872102
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer.
    Fakhry C; Qualliotine JR; Zhang Z; Agrawal N; Gaykalova DA; Bishop JA; Subramaniam RM; Koch WM; Chung CH; Eisele DW; Califano J; Viscidi RP
    Cancer Prev Res (Phila); 2016 Feb; 9(2):135-41. PubMed ID: 26701665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma.
    Hanna GJ; Sridharan V; Margalit DN; La Follette SK; Chau NG; Rabinowits G; Lorch JH; Haddad RI; Tishler RB; Anderson KS; Schoenfeld JD
    Cancer Biomark; 2017; 19(2):129-136. PubMed ID: 28387659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8
    Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
    Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and serologic markers of HPV 16 infection are associated with local recurrence in patients with oral cavity squamous cell carcinoma.
    Huang CG; Lee LA; Liao CT; Yen TC; Yang SL; Liu YC; Li JC; Gong YN; Kang CJ; Huang SF; Fang KH; Chang KP; Lee LY; Hsueh C; Shih SR; Tsao KC
    Oncotarget; 2017 May; 8(21):34820-34835. PubMed ID: 28422732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma.
    Holzinger D; Wichmann G; Baboci L; Michel A; Höfler D; Wiesenfarth M; Schroeder L; Boscolo-Rizzo P; Herold-Mende C; Dyckhoff G; Boehm A; Del Mistro A; Bosch FX; Dietz A; Pawlita M; Waterboer T
    Int J Cancer; 2017 Jun; 140(12):2748-2757. PubMed ID: 28316084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study.
    Economopoulou P; Koutsodontis G; Avgeris M; Strati A; Kroupis C; Pateras I; Kirodimos E; Giotakis E; Kotsantis I; Maragoudakis P; Gorgoulis V; Scorilas A; Lianidou E; Psyrri A
    PLoS One; 2019; 14(5):e0215984. PubMed ID: 31071126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma using droplet digital polymerase chain reaction.
    Biron VL; Kostiuk M; Isaac A; Puttagunta L; O'Connell DA; Harris J; Côté DW; Seikaly H
    Cancer; 2016 May; 122(10):1544-51. PubMed ID: 26989832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer.
    Smith EM; Pawlita M; Rubenstein LM; Haugen TH; Hamsikova E; Turek LP
    Int J Cancer; 2010 Jul; 127(1):111-7. PubMed ID: 19876924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of HPV in head and neck squamous cell carcinoma.
    Liang C; Marsit CJ; McClean MD; Nelson HH; Christensen BC; Haddad RI; Clark JR; Wein RO; Grillone GA; Houseman EA; Halec G; Waterboer T; Pawlita M; Krane JF; Kelsey KT
    Cancer Res; 2012 Oct; 72(19):5004-13. PubMed ID: 22991304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma.
    Reder H; Taferner VF; Wittekindt C; Bräuninger A; Speel EM; Gattenlöhner S; Wolf G; Klussmann JP; Wuerdemann N; Wagner S
    J Mol Diagn; 2020 Nov; 22(11):1333-1343. PubMed ID: 32822851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
    Lang Kuhs KA; Kreimer AR; Trivedi S; Holzinger D; Pawlita M; Pfeiffer RM; Gibson SP; Schmitt NC; Hildesheim A; Waterboer T; Ferris RL
    Cancer; 2017 Nov; 123(22):4382-4390. PubMed ID: 28950407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins.
    Sun Y; Shah KV; Müller M; Muñoz N; Bosch XF; Viscidi RP
    J Clin Microbiol; 1994 Sep; 32(9):2216-20. PubMed ID: 7529250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable.
    Ren J; Xu W; Su J; Ren X; Cheng D; Chen Z; Bender N; Mirshams M; Habbous S; de Almeida JR; Perez-Ordonez B; Goldstein DP; Wang JR; Bratman SV; Huang SH; Jang R; Zhao Y; Waterboer T; Hung RJ; Liu G
    Int J Cancer; 2020 Apr; 146(8):2166-2174. PubMed ID: 31269236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
    Rosales R; López-Contreras M; Cortes RR
    J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
    Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
    Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of HPV infection and survival in patients with head and neck tumors.
    Koslabova E; Hamsikova E; Salakova M; Klozar J; Foltynova E; Salkova E; Rotnaglova E; Ludvikova V; Tachezy R
    Int J Cancer; 2013 Oct; 133(8):1832-9. PubMed ID: 23564321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
    Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
    Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.
    Nindl I; Benitez-Bribiesca L; Berumen J; Farmanara N; Fisher S; Gross G; Lopez-Carillo L; Müller M; Tommasino M; Vazquez-Curiel A
    Arch Virol; 1994; 137(3-4):341-53. PubMed ID: 7524466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers?
    Smith EM; Rubenstein LM; Ritchie JM; Lee JH; Haugen TH; Hamsikova E; Turek LP
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2087-96. PubMed ID: 18708401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.